Table 2. Correlation between number of ranibizumab injections and candidate variables (all countries; over 2 years).

Parameters	Coefficienta	SE	Lower 95% CI	Upper 95% CI
Age at start of therapy	–0.0289	0.1141	–0.0378	0.056
Sex	0.0171	0.384	–0.0126	0.5193
Health insurance (public)	–0.028	0.1544	–0.053	0.0071
Reimbursement type (national standards)	0.1297	<0.001	0.1524	<0.001
Medical history (prior disease)	–0.0268	0.1711	–0.0354	0.0703
Medical history (concomitant disease)	–0.0003	0.9866	0.018	0.3595
Medical history (ocular disease)	–0.0246	0.2083	–0.0331	0.0905
Baseline VAS	–0.0088	0.6758	0.0424	0.0444
Treatment duration	0.5645	<0.001	0.7389	<0.001
Switch to other treatments	0.0275	0.1599	0.0632	0.0012
Baseline presence of retinal breaksb	NA	NA	NA	NA
Baseline presence of pigment epithelial detachment	0.0821	0.0038	0.1163	<0.001
Number of ophthalmoscopies	0.2499	<0.001	0.3425	<0.001
Optical coherence tomography, n	0.3777	<0.001	0.4955	<0.001
Fluorescein angiography, n	0.0509	0.0093	0.1154	<0.001
ICGA, n	–0.0341	0.0814	0.0302	0.1228
Ophthalmoscopies/optical coherence tomography, n	0.3608	<0.001	0.4673	<0.001
Number of monitoring visits	–0.1349	<0.001	0.0239	0.2224

Abbreviations: ICGA, indocyanine green angiography; NA, not available; VAS, visual acuity score.

^aPearson's correlation coefficient at 95% CI.

^bNo observation with retinal break episode. The bold values highlights the candidate instrumental variables.